Mar. 21 at 4:53 PM
$SNDX is the best performing comm'l-stage bio stock (in both oncology & non-oncology) as measured by its 3/20/26 close v. its 3.5 month high (since 12/1/25).
The attachment lists all 92 commercial-stage oncology (MCs over
$300MM) & non-oncology (MCs over
$900MM) bio stocks 3/20/26 closing share price v. their 3.5 month high (again since 12/1/25). The table excludes DAWN & DVAX (both recently acquired).
The
$XBI is more or less unchanged over this time (up 0.5%)
Note more than half of SNDX peers are off their recent highs by over 25%.
$BCRX comes a close second to SNDX. BCRX's strong share price is likely due to the Betaville Uncooked alert this last week suggesting BCRX is in active M&A negotiations.
$KNSA ranks third on the list
$OCUL 's share price appears to provide a textbook example of why the odds are shareholder value is maximized via M&A exit in this peer group.
As always, do not rely on the attachment. Verify the data points for yourself. This is not investment advice.
